Colorectal cancer, including MSI-high disease — a frequent target for shared-neoantigen and personalized vaccine strategies.
Log in here to read the desired article. BioNTech and Genentech have terminated a Phase 2 trial of their personalized mRNA cancer vaccine autogene cevumeran in colorectal cancer after more deaths occurred in the vaccine arm than among patients under observation. The setback comes…
Providence Health & Services is operating an expanded access program (NCT07614048) for T-cells engineered to express TCRs targeting mutant KRAS-G12D. The intermediate-size IND treats advanced pancreatic and colorectal cancers in patients with specific HLA types. This provides real-world data on the feasibility of manufacturing and administering KRAS-targeted adoptive cell therapy outside of traditional trial structures.
Identification of immunogenic neoantigens from intron retention in colorectal cancer Nature
A study from Vietnam National University developed a colorectal cancer-specific off-the-shelf neoantigen panel targeting shared mutations. By integrating TCGA mutation data with HLA class I binding predictions across 68 alleles, the team identified candidates with broad coverage for both Asian and Caucasian populations to address limitations in population-specific utility.
Researchers tested genetically modified outer membrane vesicles (OMVs) carrying poly-neoepitopes in a mouse model of colorectal cancer with lung metastasis. The approach aims to enhance immunotherapy efficacy by leveraging OMVs as a delivery platform for neoantigens, offering a potential preclinical proof-of-concept for targeted vaccine strategies.